Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
6.–10. rezultāts no 100.
38. lappuse
... statement that additives may be incompatible . ( 2 ) A statement that , if additive drugs are introduced into the paren- teral system , aseptic techniques should be used and the solution should be thoroughly mixed . ( 3 ) A statement ...
... statement that additives may be incompatible . ( 2 ) A statement that , if additive drugs are introduced into the paren- teral system , aseptic techniques should be used and the solution should be thoroughly mixed . ( 3 ) A statement ...
39. lappuse
... statement that these drugs are no longer considered safe as a test for pregnancy . ( 6 ) A statement that the patient should inform her physician as soon as possible if she discovers that she was pregnant when she took the drug . ( c ) ...
... statement that these drugs are no longer considered safe as a test for pregnancy . ( 6 ) A statement that the patient should inform her physician as soon as possible if she discovers that she was pregnant when she took the drug . ( c ) ...
41. lappuse
... statement : WARNING : Accidental overdose of iron - containing products is a leading cause of fatal poisoning in children under 6. Keep this product out of reach of children . In case of accidental over- dose , call a doctor or poison ...
... statement : WARNING : Accidental overdose of iron - containing products is a leading cause of fatal poisoning in children under 6. Keep this product out of reach of children . In case of accidental over- dose , call a doctor or poison ...
44. lappuse
... statement in the labeling indicating that " hor- mones " are present in the product , or any statement that features or empha- sizes the presence of a hormone ingre- dient in the product , will be considered to be a therapeutic claim ...
... statement in the labeling indicating that " hor- mones " are present in the product , or any statement that features or empha- sizes the presence of a hormone ingre- dient in the product , will be considered to be a therapeutic claim ...
64. lappuse
... statement " Caution : New Drug - Lim- ited by Federal ( or United States ) law to investigational use . " ( b ) The label or labeling of an inves- tigational new drug shall not bear any statement that is false or misleading in any ...
... statement " Caution : New Drug - Lim- ited by Federal ( or United States ) law to investigational use . " ( b ) The label or labeling of an inves- tigational new drug shall not bear any statement that is false or misleading in any ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning